# US 11,999,782 B2 · Therapeutic agents for the treatment of diseases associated with undesired cell proliferation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,999,782 B2
- Document ID: US11999782B2
- Status: Granted
- Kind: B2
- Application number: 17/001,530
- Filed: 2020-08-24
- Published: 2020-12-10
- Granted: 2024-06-04
- Earliest claimed: 2009-04-03
- Assignees: Fundacio Privada Institutcio Catalana de Recerca I Estudis Avancats (ICREA); Fundació Privada Institut D'Investigatió Oncológica De Vall Hebron (VHIO); Fundacio Privada Institut De Recerca Hospital Universitari Vall Hebron (Ir-Huvh)
- Applicants: Fundació Privada Institutció Catalana de Recerca I Estudis Avançats (ICREA); Fundació Privada Institut D'Investigatió Oncológica De Vall Hebron (VHIO); Fundacio Privada Institut de Recerca Hospital Universitari Vall Hebron (IR-HUVH)
- Inventors: Joan Seoane Suarez; Silvia Penuelas Prieto; José Baselga Torres
- Web page: https://patentgrep.com/patent/US11999782B2

## CPC

- C07K 16/244: {Interleukins [IL]}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 31/7115: Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
- A61K 31/7125: Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A61K 2039/505: {comprising antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 33/575: for cancer
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention is based on observing that LIF is capable of activating the self-renewal of tumor stem cells in cancer, in particular gliomas, which indicates that the inhibition of LIF, and generally of IL-6 type cytokines, can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation. The invention also relates to a method for the identification of compounds capable of blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of subjects suffering from said tumors.

## Claims

### Claim 1

A method for treating glioma in a subject in need thereof, comprising administering a therapeutically effective amount of a neutralizing antibody that specifically binds leukemia inhibitory factor (LIF); wherein the antibody inhibits proliferation of tumor stem cells.

### Claim 2 (depends on 1)

The method of claim 1, wherein the glioma is a grade IV glioma.

### Claim 3 (depends on 1)

The method of claim 1, wherein the antibody is a monoclonal antibody.